OPKO Health, Inc. (OPK)

NASDAQ: OPK · IEX Real-Time Price · USD
0.866
-0.029 (-3.27%)
At close: Mar 18, 2024, 4:00 PM
0.880
+0.014 (1.68%)
After-hours: Mar 18, 2024, 7:58 PM EDT
-3.27%
Market Cap 608.68M
Revenue (ttm) 863.50M
Net Income (ttm) -188.86M
Shares Out 696.99M
EPS (ttm) -0.25
PE Ratio n/a
Forward PE 64.52
Dividend n/a
Ex-Dividend Date n/a
Volume 10,647,556
Open 0.902
Previous Close 0.895
Day's Range 0.861 - 0.907
52-Week Range 0.850 - 2.240
Beta 1.80
Analysts Strong Buy
Price Target 2.25 (+159.97%)
Earnings Date May 1, 2024

About OPK

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers,... [Read more]

Sector Healthcare
IPO Date Nov 2, 1995
Employees 3,930
Stock Exchange NASDAQ
Ticker Symbol OPK
Full Company Profile

Financial Performance

In 2023, OPKO Health's revenue was $863.50 million, a decrease of -14.01% compared to the previous year's $1.00 billion. Losses were -$188.86 million, -42.49% less than in 2022.

Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for OPK stock is "Strong Buy." The 12-month stock price forecast is $2.25, which is an increase of 159.97% from the latest price.

Price Target
$2.25
(159.97% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

AIDS Clinical Trial Group Presents Results from Phase 1 Study of ModeX Trispecific Antibody for the Treatment and Prevention of HIV

• Study delivers first clinical safety and pharmacokinetic data as proof of concept for the use of multispecific antibodies in humans • Candidate showed similar half-life to standard monoclonal antibo...

13 days ago - GlobeNewsWire

OPKO Health Reports Fourth Quarter 2023 Business Highlights and Financial Results

MIAMI, Feb. 27, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and 12 months ended December 31, 2023. Business highlights from...

20 days ago - GlobeNewsWire

OPKO Health to Report Fourth Quarter 2023 Financial Results on February 27, 2024

MIAMI, Feb. 22, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three and 12 months ended December 31, 2023 after the close of the U.S....

25 days ago - GlobeNewsWire

OPKO Health Announces Closing of Private Offering of $230 Million Convertible Senior Notes Due 2029 including Full Exercise of Initial Purchaser's Option to Purchase Additional Notes

MIAMI, Jan. 09, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (the “Company”) today announced the closing of its previously announced private offering of $230.0 million aggregate principal ...

2 months ago - GlobeNewsWire

OPKO Health Announces Pricing of Private Offering of $200 Million Convertible Senior Notes Due 2029

Proceeds to be used for privately negotiated repurchases of common stock and outstanding 4.50% Convertible Senior Notes due 2025 Proceeds to be used for privately negotiated repurchases of common stoc...

2 months ago - GlobeNewsWire

OPKO Health Announces Private Offering of Convertible Senior Notes Due 2029

Proceeds to be used for privately negotiated repurchases of common stock and outstanding 4.50% Convertible Senior Notes due 2025 Proceeds to be used for privately negotiated repurchases of common stoc...

2 months ago - GlobeNewsWire

BioReference Health and Prognos Health Collaborate to Advance Precision Medicine and Testing

ELMWOOD PARK, N.J. , Nov. 28, 2023 /PRNewswire/ -- BioReference® Health, LLC (BRH), a leading specialty laboratory in the United States, announced a strategic collaboration with Prognos Health, a pion...

3 months ago - PRNewsWire

BioReference® Signs On as the First Laboratory to Use MSK-ACCESS® Powered with SOPHiA DDM™

World-class liquid biopsy testing will be made commercially available to BioReference® customers across the country BOSTON and ELMWOOD PARK, N.J. and ROLLE, Switzerland , Nov. 7, 2023 /PRNewswire/ -- ...

Other symbols: SOPH
4 months ago - PRNewsWire

OPKO Health Reports Third Quarter 2023 Business Highlights and Financial Results

MIAMI, Nov. 06, 2023 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and nine months ended September 30, 2023. Business highlights f...

4 months ago - GlobeNewsWire

New Clinical Data on OPKO Health's RAYALDEE® (ER Calcifediol) Presented at Kidney Week 2023

MIAMI, Nov. 02, 2023 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) presented late-breaking clinical data on RAYALDEE® extended-release calcifediol (ERC) at the American Society of Nephrology (AS...

4 months ago - GlobeNewsWire

OPKO Health to Report Third Quarter 2023 Financial Results on November 6, 2023

MIAMI, Oct. 31, 2023 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three and nine months ended September 30, 2023 after the close of the U...

4 months ago - GlobeNewsWire

OPKO Health to Present New Clinical Data on Rayaldee (ER Calcifediol) at Kidney Week 2023

MIAMI, Oct. 25, 2023 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) will present late-breaking clinical data on RAYALDEE® extended-release calcifediol (ERC) at the American Society of Nephrology ...

5 months ago - GlobeNewsWire

ModeX Therapeutics Secures BARDA Contract to Develop Novel Multispecific Antibodies Against Viral Infectious Disease Threats

Provides Initial $59 Million and up to $168 Million Contingent on Milestones Provides Initial $59 Million and up to $168 Million Contingent on Milestones

6 months ago - GlobeNewsWire

OPKO Health to Report Second Quarter 2023 Financial Results on August 3, 2023

MIAMI, July 25, 2023 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three and six months ended June 30, 2023 after the close of the U.S. fi...

8 months ago - GlobeNewsWire

FDA Approves Pfizer's NGENLA™, a Long-Acting Once-Weekly Treatment for Pediatric Growth Hormone Deficiency

NEW YORK & MIAMI--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and OPKO Health Inc. (NASDAQ: OPK) announced today that the U.S. Food and Drug Administration (FDA) has approved NGENLA (somatrogon-ghla), a ...

Other symbols: PFE
9 months ago - Business Wire

OPKO Health Reports First Quarter 2023 Business Highlights and Financial Results

MIAMI, May 03, 2023 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three months ended March 31, 2023. First quarter business highlights i...

11 months ago - GlobeNewsWire

OPKO Health to Report First Quarter 2023 Financial Results on May 3, 2023

MIAMI, April 25, 2023 (GLOBE NEWSWIRE) --  OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three months ended March 31, 2023 after the close of the U.S. financi...

11 months ago - GlobeNewsWire

OPKO Health Reports Fourth Quarter 2022 Business Highlights and Financial Results

Conference call begins at 4:30 p.m. Eastern time today Conference call begins at 4:30 p.m. Eastern time today

1 year ago - GlobeNewsWire

OPKO Health to Report Fourth Quarter 2022 Financial Results on February 23, 2023

MIAMI, Feb. 16, 2023 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three months ended December 31, 2022 after the close of the U.S. financ...

1 year ago - GlobeNewsWire

BioReference Now Offers the Only FDA-Approved Dual-Stain Triage Test to Enhance Cervical Cancer Screenings

CINtec ®  PLUS Cytology offered as a reflex test when cytology is NILM and HPV positive ELMWOOD PARK, N.J. , Feb. 9, 2023 /PRNewswire/ -- BioReference® Health LLC, one of the largest full-service spec...

1 year ago - PRNewsWire

OPKO Health to Present at the 41st Annual J.P. Morgan Healthcare Conference

MIAMI, Jan. 03, 2023 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) announced today that management will be participating in the 41st Annual J.P. Morgan Healthcare Conference being held January 9...

1 year ago - GlobeNewsWire

OPKO Health Reports Third Quarter 2022 Business Highlights and Financial Results

Conference call begins at 4:30 p.m. Eastern time today Conference call begins at 4:30 p.m. Eastern time today

1 year ago - GlobeNewsWire

OPKO Health And 2 Other Penny Stocks Are Aggressively Buying - Medalist Diversified REIT (NASDAQ:MDRR), Great Elm Group (NASDAQ:GEG)

US crude oil futures traded higher on Friday. Investors, meanwhile, focused on some notable insider trades.

Other symbols: MDRRGEG
1 year ago - Benzinga

OPKO Health Announces Leadership Changes for BioReference Laboratories

MIAMI, Aug. 16, 2022 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK), a multinational biopharmaceutical and diagnostics company, today announced that Jon R. Cohen, M.D., is retiring from his role ...

1 year ago - GlobeNewsWire

OPKO Health to Report Second Quarter 2022 Financial Results on August 4, 2022

MIAMI, July 25, 2022 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three and six months ended June 30, 2022 after the close of the U.S. fi...

1 year ago - GlobeNewsWire